GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeoImmuneTech Inc (XKRX:950220) » Definitions » Short-Term Debt

NeoImmuneTech (XKRX:950220) Short-Term Debt : ₩0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is NeoImmuneTech Short-Term Debt?

NeoImmuneTech's Short-Term Debt for the quarter that ended in Dec. 2023 was ₩0.00 Mil.


NeoImmuneTech Short-Term Debt Historical Data

The historical data trend for NeoImmuneTech's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoImmuneTech Short-Term Debt Chart

NeoImmuneTech Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Debt
- - - - -

NeoImmuneTech Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

NeoImmuneTech Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


NeoImmuneTech Short-Term Debt Related Terms

Thank you for viewing the detailed overview of NeoImmuneTech's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


NeoImmuneTech (XKRX:950220) Business Description

Traded in Other Exchanges
N/A
Address
2400 Research Boulevard, Suite 250, Rockville, MD, USA, 20850
NeoImmuneTech Inc is a clinical-stage T cell-focused biotech company dedicated to the discovery and development of novel immuno-therapeutics. Its lead asset NT-I7 is the clinical stage IL-7, which enhances the body's immune function to address key resistance mechanisms in Immuno-Oncology and deadly infectious diseases.

NeoImmuneTech (XKRX:950220) Headlines

No Headlines